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Laboratory-based surveillance of Shigella spp. from 
human clinical cases in Colombia, 1997-2018
Edna Catering Rodríguez, Adriana Marcela Bautista, Lucy Angeline Montaño, María 
Victoria Ovalle, Francia Patricia Correa 
Grupo de Microbiología, Dirección de Redes en Salud Pública, Instituto Nacional de Salud, 
Bogotá, D.C., Colombia
Introduction: Shigellosis is endemic in low-and middle-income countries, causing 
approximately 125 million episodes of diarrhea and leading to approximately 160 .000 
deaths annually one-third of which is associated with children.
Objective: To describe the characteristics and antimicrobial resistance profiles of Shigella 
species recovered in Colombia from 1997 to 2018.
Materials and methods: We received isolates from laboratories in 29 Colombian 
departments. We serotyped with specific antiserum and determined antimicrobial resistance 
and minimal inhibitory concentrations for ten antibiotics with Kirby-Bauer tests following the 
Clinical and Laboratory Standards Institute recommendations.
Results: We analyzed 5,251 isolates of Shigella spp., most of them obtained from stools 
(96.4%); 2,511 (47.8%) were from children under five years of age. The two most common 
species were S. sonnei (55.1%) and S. flexneri (41.7%). The highest resistance rate was that 
of tetracycline (88.1%) followed by trimethoprim-sulfamethoxazole (79.3%) and ampicillin 
(65.5%); 50.8% of isolates were resistant to chloramphenicol, 43.6% to amoxicillin/clavulanic 
acid, and less than 1% to cefotaxime, ceftazidime, gentamicin, and ciprofloxacin. In S. sonnei, 
the most common resistance profile corresponded to trimethoprim-sulfamethoxazole (92%) 
whereas in S. flexneri the most common antibiotic profiles were multidrug resistance.
Conclusions. In Colombia, children under five years are affected by all Shigella species. 
These findings should guide funders and public health officials to make evidence-
based decisions for protection and prevention measures. The antimicrobial resistance 
characteristics found in this study underline the importance of combating the dissemination 
of the most frequently isolated species, S. sonnei and S. flexneri.
Keywords: Dysentery, bacillary; public health surveillance; drug resistance, microbial; 
ampicillin; cephalosporins; fluoroquinolones; trimethoprim, sulfamethoxazole drug 
combination; chloramphenicol.
Vigilancia por el laboratorio de Shigella spp. aislada de casos clínicos humanos en 
Colombia, 1997-2018
Introducción. La shigelosis es endémica en los países de ingresos bajos y medios y 
ocasiona aproximadamente 125 millones de episodios de diarrea y 160.000 muertes al año, 
un tercio de los cuales se presenta en niños. 
Objetivo. Describir las características y los perfiles de resistencia antimicrobiana en 
aislamientos de Shigella spp. recuperados en Colombia entre 1997 y 2018.
Materiales y métodos. Los aislamientos provenían de laboratorios en 29 departamentos 
de Colombia. La serotipificación se hizo con antisueros específicos de Shigella spp. y, la 
determinación de los perfiles de resistencia y la concentración inhibitoria mínima de diez 
antibióticos, por Kirby-Bauer. 
Resultados. Se estudiaron 5.251 aislamientos de Shigella spp. obtenidos de materia fecal 
(96,4 %); el 47,8 % de ellos correspondía a niños menores de cinco años. Las especies 
más frecuentes fueron S. sonnei (55,1 %) y S. flexneri (41,7 %). Se presentó resistencia a 
tetraciclina (88,1 %), trimetoprim-sulfametoxasol (79,3 %), ampicilina (65,5 %), cloranfenicol 
(50,8 %) y amoxicilina-acido clavulánico (43,6 %). La resistencia no superó el 1 % contra 
cefotaxime, ceftazidima, gentamicina y ciprofloxacina. Para S. sonnei, el perfil de resistencia 
más frecuente correspondió a trimetoprim-sulfametoxasol, en contraste con S. flexneri, 
cuyos perfiles fueron todos multirresistentes. 
Conclusiones. Los niños menores de cinco años se vieron afectados por todas las 
especies de Shigella spp., aspecto que los legisladores en salud pública deben considerar 
a la hora de tomar decisiones en torno a las medidas de prevención y protección frente a 
esta enfermedad. Las características de resistencia antimicrobiana de los aislamientos de 
Shigella spp. en Colombia ponen de manifiesto la importancia de combatir la diseminación 
de las dos especies más frecuentes en casos clínicos, S. sonnei y S. flexneri.
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Diarrhea is a major global health issue causing 1.3 million deaths each 
year 500.000 of which occur in children less than five years of age (1). 
Shigellosis is endemic in most low- and middle-income countries and is the 
most important cause of bloody diarrhea worldwide (2). Recent estimates 
attribute to Shigella spp. approximately 125 million diarrhea episodes annually 
leading to approximately 160,000 deaths one-third of which are associated 
with young children (1,3). The Global Enteric Multicenter Study revealed that 
Shigella spp. was the most prevalent causative agent in children aged 2 to 5 
years who experienced diarrhea and suggested that the induced burden may 
be twice as high as previously estimated (4).
Shigella genus is divided into the following four species and into multiple 
serotypes dependent on O-antigen and biochemical differences: Shigella 
dysenteriae (serogroup A, 15 serotypes), Shigella flexneri (serogroup B, 19 
serotypes), Shigella boydii (serogroup C, 20 serotypes), and Shigella sonnei 
(serogroup D, 1 serotype) (5). The pathogen spreads by direct contact with 
an infected person or by ingesting contaminated food or water. The infective 
dose can be as low as 10 microbes; its global importance arises from its wide 
distribution and water quality concerns that make it an important risk for public 
health (6). Shigella sonnei and S. boydii usually cause relatively mild illness 
with watery or bloody diarrhea while S. flexneri is the chief cause of endemic 
shigellosis in low- and middle-income countries (7).
Many observations have concluded that Shigella species are 
geographically stratified based on the level of economic development in each 
country. Shigella flexneri is the primary infectious species in low- and middle-
income countries and S. sonnei rates increase with economic development. 
Shigella boydii is usually restricted to Bangladesh and South-East Asia rarely 
occurring outside these regions while S. dysenteriae type 1 (Sd1) outbreaks 
occur sporadically (8). Emerging multidrug-resistant Shigella isolates have 
exacerbated the public health impact of shigellosis leading to increased 
morbidity, mortality, and treatment costs (2,9).
Given that Shigella is a major contributor to the global diarrhea burden, 
vaccination can be an effective strategy to prevent the disease. However, there 
are at least 50 recognized Shigella serotypes and their distribution differs 
among geographical regions hindering vaccine development (10).
Public health significant microorganisms in Colombia include Shigella 
spp. and Salmonella spp. These species are part of the surveillance of acute 
diarrheal diseases by public health laboratories and the Laboratorio de 
Microbiología at the Instituto Nacional de Salud. Given the need to better 
understand the behavior of Shigella species at a national level, we report 
here the age of the population affected, the temporal and geographical 
characteristics of the isolates, and the antimicrobial resistance profiles of 
Shigella species recovered in the country from 1997 to 2018.
Materials and methods
Strains recovered from patients were collected in hospitals or public health 
laboratories and then sent to the Laboratorio de Microbiología at the Instituto 
Nacional de Salud to confirm their biochemical identification following the 
standardized procedures and to serotype them using commercial polyclonal 
and monoclonal typing antisera (Eurobium) in the framework of the acute 
diarrheal disease surveillance program (11). 
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Antimicrobial resistance was determined using the Kirby-Bauer test 
against tetracycline (30 μg), chloramphenicol (30 μg), nalidixic acid (30 μg), 
amoxicillin/clavulanic acid (10 μg), and ciprofloxacin (5 μg). Additionally, we 
obtained the minimal inhibitory concentrations (MIC) for ampicillin (8-16 μg/
ml), cefotaxime (2-32 μg/ml), ceftazidime (1-16 μg/ml), ciprofloxacin (1-2 
μg/ml), gentamicin (4-86 μg/ml), and trimethoprim-sulfamethoxazole (2/38 
μg/ml) with the Microscan® (Siemens) automated system following the 
recommendations of the Clinical and Laboratory Standards Institute yearly 
updated (12). Statistical significance (p value) was calculated with EpiInfo 7.
Results
We studied 5,251 isolates of Shigella spp. recovered in 29 Colombian 
departments. Bogotá, the country’s capital city, sent the highest number 
of isolates (n=3,257, 62%). Another five states recovered more than one 
hundred isolates each: Antioquia (n=814; 15%); Valle (n=205; 3.9%); Norte de 
Santander (n=187; 3.6%); Nariño (n=157; 3%), and Boyacá (n=146; 2.8%). 
The additional 485 isolates were recovered from the other 23 departments.
The majority of isolates were obtained mainly from stools (96.4%; 
5,063/5,251) of patients whose ages ranged from newborns to 92 years. 
The children under one year of age contributed 452 isolates (8.6%), and the 
patients between 2 and 5 years contributed 2,059 isolates (39.2%); 1,498 
(28.5%) isolates were recovered from 6 to 14-year-old patients while 904 
isolates (17.2%) were recovered from those over 15 years (Table 1).
Two species were predominant representing together 96% of the strains: 
2,896 (55.1%) isolates were S. sonnei and 2,191 (41.7%) were S. flexneri. 
Other species included S. boydii and S. dysenteriae with 103 and 14 isolates 
each. Some of the isolates had some of the typical characteristics of Shigella 
but it was not possible to identify them at the species level and, therefore, 
they were labeled as non-serotypeable Shigella. Non-serotypeable Shigella 
accounted for approximately 47 isolates, none of which were agglutinated with 
any antisera of the established Shigella serovars.
During the first three years of surveillance (1997-1999), S. flexneri was the 
dominant species decreasing after 2002 when S. sonnei became the most 
dominant and continued to be for 15 years, until 2016, when it became again 
the second most common strain (figure 1).
The highest resistance level was found for tetracycline (88.1%) followed 
by trimethoprim-sulfamethoxazole (79.3%), and ampicillin (65.5%); 50.8% 
of isolates were resistant to chloramphenicol and 43.6% to amoxicillin/
clavulanic acid. Less than 1% of the isolates were resistant to cephalosporins 
(cefotaxime and ceftazidime), gentamicin, and ciprofloxacin (table 2).
NC: Information not collected
Table 1. Age and sample distribution
Age in years



































Total 452 2,059 1,498 904 338 5,251
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Geographical distribution, age, and antimicrobial resistance of species
Shigella sonnei
Geographical distribution: S. sonnei represented more than half of the 
Colombian Shigella spp. isolates evaluated (2,896, 54.7%); 66% (1,975/2,896) 
of the isolates under study were recovered in Bogotá: 58 isolates detected 
in 2001 and 101 in 2002; 16% of isolates were recovered in Antioquia while 
the remaining 17.8% were from the other 25 departments where the recovery 
increased between 2011 and 2014 as the highest number of isolates for this 
species came from those states in the last few years (figure 2).
There were 23 outbreaks in nine different departments (Antioquia, Bogotá, 
Boyacá, Cundinamarca, Nariño, Norte de Santander, Santander, Sucre, and 
Valle) with 80 related isolates. The outbreak that grouped most cases (12) 
occurred in Nariño in 2008. The isolates recovered in the other outbreaks 
registered there varied.
Age: Almost half of the isolates (48%, 1390/2896) were recovered from 
children under 6 years of age. In the 6 to 14-year age group, S. sonnei was the 
most frequently recovered (32.6% of isolates; 943/2896) (table 3).
Antimicrobial resistance: S. sonnei showed the highest resistance to 
trimethoprim-sulfamethoxazole (89.6%; 2,530/2,825) and to tetracycline (more 
than 80%; 2,278/2,714). Resistance levels for nalidixic acid, chloramphenicol, 
amoxicillin/clavulanic acid, and ampicillin were 7% (184/2,574), 29.4% 
(803/2,733), 32.8% (785/2,391), and 52% (1469/2827), respectively (table 2); 
14 isolates were resistant to ciprofloxacin, 12 to cefotaxime, 10 to ceftazidime, 
and 7 to gentamicin.
Figure 1. Distribution of Shigella spp. isolates in Colombia from 1997 to 2018. S. flexneri (grey), S. sonnei 
(black), and other species (dashed line). This information was based on the annual Shigella surveillance 
system in Colombia.
AMC: Amoxicillin/clavulanic acid; TE: Tetracycline; C: Chloramphenicol; NA: Nalidixic acid; 
CAZ: Ceftazidime; CTX: Cefotaxime; AMP: Ampicillin; SXT: Trimethoprim-sulfamethoxasole; 
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Total 43.6 88.1 50.8  5.13 0.36 0.41 65.5 79.3 0.46 0.34
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Shigella flexneri
A total of 321/2,191 isolates (14.65%) were detected in Antioquia with 
increases in 2000, 2006, and 2012. Another 627 (28.6%) isolates were 
recovered in 25 departments representing an increase as of 2016. Eleven 
outbreaks of S. flexneri were notified (figure 3) with 37 related isolates in five 
departments (Amazonas, Bogotá, Cundinamarca, Meta, and Nariño). The 
most important outbreak occurred in Cundinamarca in 2001 when 14 isolates 
were related to food consumed in a school (Figure 3).
NC: information not collected
Figure 2. Comparison of the number and distribution of Shigella sonnei isolates in Antioquia (black), Bogotá (grey), and other 




























Table 3. Age range and Shigella species distribution
Shigella species




































Figure 3. Comparison of the number and distribution of Shigella flexneri isolates in Antioquia (grey), Bogotá (black), and others regions 
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Age: The number of S. flexneri isolates by age groups was similar. 
However, almost half of the isolates (48.5%) were recovered in under six-year-
old children (table 3).
Antimicrobial resistance: S. flexneri highest resistance rates were to 
tetracycline (94.3% of isolates), ampicillin (83%), chloramphenicol (80.8%), 
and trimethoprim-sulfamethoxazole (67.8%) (table 2). Less than 10 isolates 
were resistant to ciprofloxacin, cefotaxime, ceftazidime, and gentamicin.
Other species
Geographical distribution: Out of a total of 164 isolates, 103 were S. boydii, 
14 were S. dysenteriae, and 47 were non-serotypeable Shigella isolates. 
The highest number of S. boydii isolates was recovered in 2004 and 2006, 
the largest number being 42/103 (41%). Shigella dysenteriae only appeared 
in seven of the 22 years surveilled. The highest number of S. dysenteriae 
isolates (6) was recovered in 2018 from Arauca (3), Bogotá (2), and Norte de 
Santander (figure 4). Shigella dysenteriae was not related to outbreaks.
Age: S. boydii was recovered mostly in under 14-year-olds (71%) while S. 
dysenteriae was recovered mostly from the >15-year-old population. Non-
serotypeable isolates were recovered in patients of all ages (table 3).
Antimicrobial resistance: S. boydii exhibited resistance to all evaluated 
antibiotics except ciprofloxacin. More than 75% of S. boydii isolates were 
resistant to ampicillin and tetracycline and half of these were resistant to 
trimethoprim-sulfamethoxazole.
Shigella dysenteriae was resistant to five of the ten evaluated antibiotics 
with a lower resistance rate than other species. However, the highest 
percentage of resistance to nalidixic acid was found in S. dysenteriae when 
compared with other evaluated species (11.1%).
Non-serotypeable isolates showed resistance to seven of the evaluated 
antibiotics; characteristically, this group had the greatest resistance rate to 
ciprofloxacin (2.1%) (table 2).
Figure 4. Comparison of the number and distribution of Shigella species different to sonnei and flexneri in Antioquia (black), Bogotá (grey), and other 
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Antimicrobial resistance evaluated per year and species
Beta-lactam antibiotics
Amoxicillin/clavulanic acid: S. sonnei resistance began to appear in 2006 
when 24.6% of the isolates were resistant; eleven years later, in 2017, this 
resistance rate reached its highest level of almost 66% (p<0.05). In 2018 the 
resistance level significantly decreased (11.6%; p<0.05) (Table 4).
During the first five years of surveillance of S. flexneri, no resistance was 
recorded. Nonetheless, between 2002 and 2005, rates ranged from 22% to 
40.9%; a year later, in 2006, they had increased significantly to 71.3% (p<0.05), 
and then they were stable until 2018 when there was a significant decrease 
to 35.2% (p<0.05). This was also observed in S. sonnei isolates. In the other 
species, resistance was detected in nine of the 22 years under surveillance 
and the highest resistance level was detected in 2017 (50%) (Table 4).
Ampicillin: Since surveillance started in 1997 and for 12 years, the 
resistance in S. sonnei has remained above 50%. In 2010, resistance rates 
increased significantly to 71.5% (p<0.05) and were stable until 2018 when they 
decreased significantly to 25.9% (p<0.05). In contrast, S. flexneri resistance 
rates to ampicillin remained high in the same period of time ranging from 
62.7% to 92.8% (table 4). There were no resistant isolates from other species 
only in 2008, 2015, and 2017 (table 4).
Cefotaxime and ceftazidime: Resistance to cefotaxime was found in 21 
isolates: 12 S. sonnei, 8 S. flexneri, and 1 S. boydii isolate while we detected 16 
resistant isolates to ceftazidime: 10 S. sonnei, 4 S. flexneri, and 2 S. boydii isolates.




97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18
Tetracycline
sonnei 2,714 100 95.0 85.7 95.2 94.9 96.3 97.4 90.8 92.3 92.4 92.0 93.7 82.8 85.6 81.6 86.3 70.0 70.2 70.3 64.2 62.5 41.2
flexneri 2,137 96.2 96.2 97.9 95.5 97.6 98.1 98.3 95.8 96.9 97.7 95.7 95.1 90.5 99.1 91.4 91.7 91.2 95.0 90.6 87.0 95.9 83.3
Others 162 100.0 100.0 60.0 100.0 77.8 100.0 90.0 94.1 71.4 100.0 100.0 0.0 33.3 66.7 66.7 54.5 75.0 57.1 50.0 66.7 0.0 37.5
Nalidixic acid
sonnei 2,574 0.0 0.0 0.0 0.0 0.0 0.6 1.3 1.1 2.4 4.2 1.7 2.1 4.0 3.0 7.0 12.8 18.6 9.4 14.1 6.3 38.1 25.0
flexneri 1,882 0.0 0.0 0.0 1.9 1.2 0.9 0.0 2.4 3.1 1.1 2.9 0.0 4.8 3.4 1.3 0.7 2.2 3.4 0.0 20.0 6.0 5.3
Others 146 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.9 0.0 0.0 0.0 0.0 0.0 66.7 33.3 9.1 0.0 16.7 10.0 0.0 0.0 0.0
Amoxicillin/clavulanic acid
sonnei 2,391 0.0 0.0 0.0 0.0 0.0 3.2 5.9 3.4 5.4 24.6 17.0 38.0 33.3 59.9 40.4 57.3 43.2 64.7 43.8 49.0 65.9 11.6
flexneri 1,755 0.0 0.0 0.0 0.0 0.0 23.4 37.8 22.0 40.9 71.3 66.7 80.0 72.4 76.1 74.3 75.7 78.8 81.7 76.0 62.5 85.5 35.2
Others 130 0.0 0.0 0.0 0.0 0.0 0.0 11.1 0.0 9.5 27.3 28.6 0.0 0.0 33.3 0.0 9.1 0.0 28.6 22.2 0.0 50.0 0.0
Ampicillin
sonnei 2,827 38.9 35.0 23.8 36.1 35.9 30.7 35.9 37.7 36.9 48.7 41.2 51.8 43.4 71.5 60.1 74.2 64.5 72.7 71.4 64.2 54.7 25.9
flexneri 2,166 82.8 88.7 81.3 72.7 62.7 76.4 78.2 86.9 78.3 90.8 80.0 87.7 86.7 87.3 80.4 87.5 86.0 88.5 88.0 83.3 92.8 81.6
Others 160 50.0 100.0 40.0 66.7 66.7 87.5 90.0 88.2 66.7 100.0 100.0 0.0 50.0 66.7 50.0 54.5 25.0 40.0 0.0 33.3 0.0 33.3
Trimethoprim-sulfamethoxazole
sonnei 2,825 94.4 85.0 76.2 91.6 89.7 92.0 94.8 87.4 94.6 96.6 89.3 95.0 91.9 89.7 75.9 79.0 92.2 94.2 96.9 94.3 87.3 86.6
flexneri 2,166 82.8 73.6 85.4 83.0 83.1 80.2 84.9 78.6 78.3 79.3 71.4 69.1 66.7 56.8 58.8 50.0 57.4 56.4 88.0 51.9 48.5 48.8
Others 160 50.0 0.0 40.0 66.7 66.7 25.0 50.0 47.1 66.7 81.8 71.4 0.0 16.7 0.0 50.0 45.5 75.0 40.0 62.5 66.7 100.0 44.4
Chloramphenicol
sonnei 2,733 11.1 5.0 0.0 1.2 2.6 0.6 9.2 13.7 11.9 16.8 11.4 30.3 20.2 42.5 37.7 60.3 51.4 59.9 54.3 53.8 50.0 21.6
flexneri 2,149 69.0 88.7 75.0 64.8 83.1 74.5 84.0 75.6 78.1 87.4 85.5 87.7 85.7 86.3 83.6 85.4 83.1 85.0 75.0 75.9 74.2 76.6
Others 164 50.0 0.0 20.0 0.0 11.1 0.0 20.0 5.9 14.3 18.2 14.3 0.0 0.0 0.0 16.7 9.1 25.0 57.1 40.0 33.3 0.0 11.1
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Tetracycline: From the very first year of S. sonnei surveillance, we found 
resistance levels in more than 90% of the isolates which decreased to 70% 
as of 2013 reaching the lowest levels in 2018 with 41.2%. Shigella flexneri 
isolates showed more than 90% resistance during 17 of the surveillance years 
registering the lowest rates (83.3%) in 2018. Resistance rates in other species 
fluctuated: in some years there were no resistant isolates (2008 and 2017) 
while resistance levels reached 100% in 1997, 1998, 2000, 2002, 2006, and 
2007 (Table 4).
Trimethoprim-sulfamethoxazole: In S. sonnei, resistance remained constant 
during the study period ranging from 75.9% to a maximum of 96.6% in 2006 
and 2015, respectively. In S. flexneri resistance levels exceeded 65% until 2010 
and then decreased to 48.8% in 2018. Regarding other species, resistance 
rates varied more: in 1998, 2008, and 2010, isolates were completely sensitive 
while in 2017 resistance rates reached 100% (table 4).
Quinolones and fluoroquinolones: Resistance to nalidixic acid in S. sonnei 
was higher than in other species remaining stable (below 10%) until 2012 with 
a maximum level in 2017 (38.1%). In 2016 alone, S. flexneri resistant isolates 
exceeded 20% while in other years this level did not exceed 6% (table 4). 
Ciprofloxacin-resistant isolates amounted to only 24: S. sonnei (14), S. flexneri 
(9), and S. boydii (1).
Phenicols: The highest resistance rate was detected in S. flexneri with 
more than 70% of isolates during surveillance years. In S. sonnei isolates, 
resistance rates were less than 30% until 2008, when they began to increase 
until reaching 60.3% in 2012. For other species, resistance levels varied 
during the surveillance years (table 4).
Aminoglycosides: Gentamicin was evaluated within the aminoglycoside 
class and we detected 12 resistant isolates: seven were S. sonnei, four S. 
flexneri, and one S. boydii.
Resistance profiles
The most frequent resistance profile was detected in 1,001/5,043 (19.8%) 
isolates and it corresponded to multidrug resistance (resistance to three or 
more antibiotic classes: (TE-C-AMC-AMP-SXT) (Table 5). Resistance rates 
were similar in S. flexneri and S. sonnei (Table 5).
Other resistance profiles were specific for each species. The most frequent 
in S. flexneri were TE-C-AMP (91.6%), TE-C-SXT (87.7%), TE-C-AMC-AMP 
(83.5%), and TE-C-AMP-SXT (77.5%). Interestingly, the main S. sonnei 
resistance profile was to SXT solely (92%; 277/301) followed by resistance 
to two antibiotics: TE-SXT (86%; 825/959). Furthermore, compared with S. 
flexneri, fewer multidrug-resistant isolates from other species were detected. 
TE-AMC-AMP-SXT: 78.2%; AMP-SXT: 77.9%, and TE-AMP-SXT: 75.6% were 
the most frequent resistance profiles (table 5).
Discussion
Diarrheal diseases continue to cause morbidity and mortality in low- and 
middle-income countries. Estimates from 195 countries reveal that global 
diarrhea mortality among individuals older than 5 years has been dominated 
by Shigella spp. (13). Additionally, Shigella spp. was the leading cause of 
diarrheal mortality among people older than 70 years (14,15).
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In this report, most of the strains were isolated from under 6-year-
old children. Shigella sonnei resistance profile included trimethoprim-
sulfamethoxazole solely, which indicates that age could be an important factor 
in acquiring Shigella infection in Colombia. The findings we present were 
supported by a prospective surveillance study also performed in Colombia to 
determine the incidence of Shigella spp. in acute gastroenteritis that revealed 
that 23% of the isolates were associated with hospitalization and outpatient 
care in single infections and coinfections among children between 24 and 
59 months of age (16). As described in the Global Enteric Multicenter Study 
(GEMS), Shigella spp. burden increased proportionally with age and became 
the second most common pathogen identified among 12 to 23 months 
children and the leading pathogen among 24 to 59 months ones (17).
The dominant species was S. flexneri in the first three years (1997 to 
1999) and in the last three years of surveillance (2016 to 2018). Since 2000 
and for 16 years (2000 to 2015), the dominant species was S. sonnei in all 
the departments under study. This ‘replacement phenomenon’ has been 
documented in many countries in different regions of the world such as Asia 
and it supports the emergence of S. sonnei replacing S. flexneri as the most 
frequent agent of shigellosis in economically transitional states (18,19). 
Shigella sonnei and S. flexneri were the most common isolates coinciding 
with reports at global level. For example, reports on the incidence of several 
Shigella species in countries of the Americas evidenced their presence in 
an urban community in Ecuador and in a Chilean periurban area (20,21). 
Additionally, the current global epidemiological burden for shigellosis is 
attributed to these two species: S. flexneri, conventionally associated with low- 
and middle-income countries, and S. sonnei with high-income regions (19) .
Noticeably, regions that had undergone significant industrialization 
reported increasing cases of S. sonnei compared to low- and middle-income 
areas where S. flexneri levels have remained high (22). It has been suggested 
that this shifting trend may be due to an improvement of overall nutritional 
status (23), socioeconomic level, and sanitation conditions (24). It has also 
been suggested that such shift is mediated by cross-immunity. In less-
developed countries, repeated ingestion of Plesiomonas shigelloides bacteria 
through consumption of untreated surface waters may stimulate cross-
protection against S. sonnei with O antibodies mediating protection (25).
AMC: Amoxicillin/clavulanic acid; TE: Tetracycline; C: Chloramphenicol; NA: Nalidixic acid; CAZ: Ceftazidime; 
CTX: Cefotaxime; AMP: Ampicillin; SXT: Trimethoprim sulfamethoxasole; CIP: Ciprofloxacin; GM: Gentamicin
Table 5. Antimicrobial resistance profiles distribution in different Shigella species 
Shigella species
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Total 2,141 2,761 93 6 42 5,043
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The appearance of S. flexneri in our study as the most common species 
during the last three years of surveillance could be an indicator of a decline 
in the quality of water supply and good sanitation in Colombian communities. 
It has been shown that an increase in the provision of clean water and 
sanitation possibly disrupts S. flexneri traditional transmission route (26).
Regarding the other species evaluated in our report, S. boydii and S. 
dysenteriae, we observed fewer isolates, which agrees with other worldwide 
reports (10,17,27), but outbreaks of both species have been reported (28,29).
We recovered S. dysenteriae isolates sporadically, one or two strains during 
the 23 years of surveillance. However, in 2018, six isolates were recovered from 
three different departments, two of them located in borders (Arauca and Norte 
de Santander); isolates of these species had not been previously reported in 
these states. According to previous reports, their presence may indicate the 
possibility of an epidemic in these or other regions within Colombia (30).
These isolates were evaluated for the presence of Shiga toxin and were 
negative. Some did not react with any Shigella serogroup/serotype-specific 
antisera. Other studies have found similar results with strains classified as 
untypable by serotyping in many other countries (31-33).
Regarding the antimicrobial resistance profiles of species under study, 
we found the highest resistance levels to tetracycline, trimethoprim-
sulfamethoxazole, and ampicillin, a trend also observed in Africa, Asia, and 
other South American countries where ampicillin resistance rates were high 
for almost all Shigella species. In most of the studies in Africa and Asia, 
Shigella serogroups developed resistance to tetracycline, chloramphenicol, 
and trimethoprim-sulfamethoxazole (34-36).
Additionally, resistance levels to amoxicillin/clavulanic acid reached almost 
50% in our study, which was higher than the Latin American mean reported by 
the Antimicrobial Surveillance Program where 27% of the isolates were resistant 
to this antibiotic but less frequent than the 71% reported in Europe (35).
Resistance rates to cefotaxime, ceftazidime, gentamicin, and ciprofloxacin 
were less than 1%. In general, the antimicrobial resistance level for these 
antibiotics is similar across Latin America where ceftriaxone is active against 
all Shigella spp. and fluoroquinolone-resistant isolates are limited (35,37).
The antimicrobial resistance against specific species revealed that S. 
sonnei had the highest resistance level to trimethoprim-sulfamethoxazole. 
Indeed, S. sonnei resistant isolates were found in all surveillance years. The 
resistance to amoxicillin/clavulanic acid reached its highest rate in 2017 and 
abruptly decreased by more than 50% during 2018, which was unexpected 
considering the behavior of the isolates reported herein.
Only 6% of S. flexneri isolates were susceptible to tetracycline, which 
means that more than 90% of the population is resistant. Likewise, ampicillin 
and chloramphenicol resistance were higher in S. flexneri isolates than in 
all other evaluated species. A similar situation has been revealed in other 
parts of the world with high rates of resistance to at least one of the common 
antibiotics such as ampicillin, tetracycline, and chloramphenicol (38,39).
Contrary to reports of S. flexneri resistance to gentamicin, nalidixic acid, 
and ciprofloxacin (34) in other regions, our resistant isolates did not reach 
high resistance levels. A similar situation occurred for cephalosporin where 
resistance was less than 1%, similar to that reported by Lima, et al. (40).
75
Biomédica 2021;41:65-78 Laboratory-based surveillance of Shigella spp. in Colombia, 1997-2018
The S. boydii isolate we analyzed here exhibited resistance to all antibiotics 
evaluated except for ciprofloxacin. Interestingly, this species had the highest 
resistance rates to cephalosporin and gentamicin. Regarding tetracycline, 
ampicillin, and trimethoprim-sulfamethoxazole, the trend was similar to 
previous reports (34).
We found the highest percentage of resistance to nalidixic acid in S. 
dysenteriae isolates, similar to those in India and Bangladesh where an 
alarming 82% resistance in this species was reported (41,42). In Egypt, 
Wasfy, et al., found over 50% resistance levels to chloramphenicol, 
tetracycline, and ampicillin (43,44). However, compared to other studies 
(31,45), in ours the isolates had lower levels of resistance to other antibiotics 
evaluated and were completely sensitive to amoxicillin/clavulanic acid, 
ceftazidime, cefotaxime, and ciprofloxacin.
An increase in fluoroquinolone resistance in S. flexneri and S. sonnei isolates 
in high-income countries has been reported and, although nalidixic acid 
resistance was common among S. sonnei isolates, the trend of fluoroquinolone 
resistance is slowly increasing (46,47). Oral ciprofloxacin can achieve high 
concentrations in serum and stool and has activity against Shigella isolates. 
However, ciprofloxacin should not be prescribed for children (48).
In Colombia, quinolones are not generally recommended for shigellosis 
treatment, which may have contributed to the low levels of resistance 
observed. Macrolide azithromycin is widely used in children and is 
recommended as an alternative therapy for the treatment of shigellosis 
in adults infected with multidrug-resistant isolates (49); however, in vitro 
azithromycin susceptibility testing is not routinely performed by the country’s 
Shigella surveillance system.
Our laboratory-based surveillance of Shigella spp. determined that children 
under five years of age were affected by all of them. These findings should 
be considered by funders and public health officials to make evidence-based 
decisions for effective protection and prevention including attainable vaccines. 
Characteristically, an increased frequency of multidrug resistant S. flexneri 
was observed. Following international epidemiological trends, S. sonnei is 
likely to become more prevalent on a global scale as countries increase their 
level of development and sanitation. Combating the spread of global antibiotic 
resistance will be greatly benefited by focusing on S. sonnei surveillance while 
more localized efforts are needed to combat S. flexneri resistance.
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